Testing a new short treatment for latent tuberculosis infection in primates with HIV
Official title: Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection
Funded at University of California Los Angeles · NIH-11044206 · Data updated 2026-11-12
This study is testing a new way to treat latent tuberculosis infection that could make treatment faster and easier for people, especially those with weakened immune systems, by finding the best combination of three medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | March 1, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $931,829 |
| NIH project number | 5R01AI183978-02 |
| Project ID | NIH-11044206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with latent tuberculosis infection, especially those who are co-infected with HIV or have other immunocompromising conditions.
✕Less likely to help
Patients who do not have latent tuberculosis infection or are not immunocompromised may not benefit from this research.
What this research studies
This research investigates a new treatment regimen for latent tuberculosis infection (LTBI) that could significantly shorten the duration of therapy. By using an artificial intelligence-enabled platform, the study aims to identify the most effective combinations of three drugs: clofazimine, bedaquiline, and pyrazinamide. The research is conducted in a setting that mimics HIV co-infection, which is crucial since many individuals with LTBI are at risk of reactivation due to compromised immune systems. If successful, this approach could lead to a much shorter treatment duration, making it easier for patients to complete their therapy.
Why it matters
Potential benefit: If successful, this research could provide a more effective and shorter treatment option for latent tuberculosis infection, particularly for those with compromised immune systems.
How similar studies have gone: Previous research has shown promise in using AI to optimize drug combinations for tuberculosis treatment, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Horwitz, Marcus Aaron — University of California Los Angeles
- Study coordinator: Horwitz, Marcus Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.